- Home
- ENLT vs HRMY Comparison
ENLT vs HRMY Comparison
Compare ENLT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- HRMY
- Stock Information
- Founded
- ENLT 2008
- HRMY 2017
- Country
- ENLT Israel
- HRMY United States
- Employees
- ENLT N/A
- HRMY N/A
- Industry
- ENLT
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- ENLT
- HRMY Health Care
- Exchange
- ENLT Nasdaq
- HRMY Nasdaq
- Market Cap
- ENLT 2.0B
- HRMY 2.0B
- IPO Year
- ENLT 2023
- HRMY 2020
- Fundamental
- Price
- ENLT $22.89
- HRMY $31.70
- Analyst Decision
- ENLT Buy
- HRMY Strong Buy
- Analyst Count
- ENLT 3
- HRMY 9
- Target Price
- ENLT $19.67
- HRMY $54.22
- AVG Volume (30 Days)
- ENLT 39.3K
- HRMY 627.2K
- Earning Date
- ENLT 08-06-2025
- HRMY 08-05-2025
- Dividend Yield
- ENLT N/A
- HRMY N/A
- EPS Growth
- ENLT 90.47
- HRMY 13.13
- EPS
- ENLT 0.98
- HRMY 2.62
- Revenue
- ENLT $397,296,000.00
- HRMY $744,852,000.00
- Revenue This Year
- ENLT $355.90
- HRMY $20.10
- Revenue Next Year
- ENLT $42.83
- HRMY $18.01
- P/E Ratio
- ENLT $23.31
- HRMY $12.13
- Revenue Growth
- ENLT 44.42
- HRMY 20.62
- 52 Week Low
- ENLT $14.01
- HRMY $26.47
- 52 Week High
- ENLT $23.88
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- ENLT 77.00
- HRMY 38.57
- Support Level
- ENLT $18.22
- HRMY $31.25
- Resistance Level
- ENLT $23.60
- HRMY $32.46
- Average True Range (ATR)
- ENLT 0.50
- HRMY 1.00
- MACD
- ENLT 0.35
- HRMY -0.37
- Stochastic Oscillator
- ENLT 95.35
- HRMY 11.69
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.